Racial and Ethnic Minorities at the Highest Risk of Uncontrolled Moderate-to-Severe Asthma: A United States Electronic Health Record Analysis.
Medicaid
asthma
uncontrolled
underserved
Journal
Journal of asthma and allergy
ISSN: 1178-6965
Titre abrégé: J Asthma Allergy
Pays: New Zealand
ID NLM: 101543450
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
07
2022
accepted:
31
03
2023
medline:
18
5
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
epublish
Résumé
The identification of risk factors associated with uncontrolled moderate-to-severe asthma is important to improve asthma outcomes. Aim of this study was to identify risk factors for uncontrolled asthma in United States cohort using electronic health record (EHR)-derived data. In this retrospective real-world study, de-identified data of adolescent and adult patients (≥12 years old) with moderate-to-severe asthma, based on asthma medications within 12 months prior to asthma-related visit (index date), were extracted from the Optum There were 402,403 patients in the EHR between January 1, 2012, and December 31, 2018, who met the inclusion criteria and were analyzed. African American (AA) race (hazard ratio [HR]: 2.08), Medicaid insurance (HR: 1.71), Hispanic ethnicity (HR: 1.34), age of 12 to <18 years (HR 1.20), body mass index of ≥35 kg/m This large study demonstrates multiple risk factors for uncontrolled asthma. Of note, AA and Hispanic individuals with Medicaid insurance are at a significantly higher risk of uncontrolled asthma versus their White, non-Hispanic counterparts with commercial insurance.
Identifiants
pubmed: 37200709
doi: 10.2147/JAA.S383817
pii: 383817
pmc: PMC10187653
doi:
Types de publication
Journal Article
Langues
eng
Pagination
567-577Informations de copyright
© 2023 George et al.
Déclaration de conflit d'intérêts
George M: AstraZeneca: Speaker and consultant; Teva, Genentech, and Sanofi: Consultant. Camargo CA: AstraZeneca and Sanofi: Scientific advisory board member; GSK: Consultant. Burnette A: Sanofi, Regeneron, Amgen, and AstraZeneca: Member of scientific advisory board member and Speaker; GSK, Sanofi, Regeneron, and Amgen: Consultant. Chen Y: Former employee of Sanofi at the time of the study conduct and may hold stock and/or stock options in the company. Chen Y is currently employee of Meta Platforms, Inc., Hacker Way, Menlo Park, CA, USA. Pawar A: Current employee of Sanofi and may hold stock and/or stock options in the company. Molony C: Former employee of Sanofi at the time of the study conduct and may hold stock and/or stock options in the company. Molony C is currently employee of IDEXX, Westbrook, ME, USA. Auclair M: Former employee of Sanofi at the time of study conduct and may hold stock and/or stock options in the company; current employee for Novartis Pharmaceuticals. Wells MA: Former employee of Sanofi at the time of study conduct and may hold stock and/or stock options in the company; current employee/Shareholder for Novartis Pharmaceuticals. Ferro TJ: Former employee of Sanofi at the time of the study conduct and may hold stock and/or stock options in the company. Ferro TJ is currently employee of Sun Pharma, Princeton, NJ, USA. The authors report no other conflicts of interest in this work.
Références
J Am Med Inform Assoc. 2009 May-Jun;16(3):371-9
pubmed: 19261943
J Asthma. 2022 May;59(5):1030-1040
pubmed: 33902380
Ann Am Thorac Soc. 2018 Mar;15(3):348-356
pubmed: 29323930
Am Health Drug Benefits. 2019 Jun-Jul;12(4):188-197
pubmed: 31428236
J Allergy Clin Immunol. 2012 Dec;130(6):1302-6
pubmed: 23069492
Allergy. 2008 May;63(5):564-9
pubmed: 18394130
J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138
pubmed: 17983880
Respir Med. 2007 Mar;101(3):481-9
pubmed: 16914299
J Allergy Clin Immunol. 2011 Jan;127(1):145-52
pubmed: 21211649
Clin Rev Allergy Immunol. 2019 Apr;56(2):219-233
pubmed: 30206782
AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:123-132
pubmed: 28815121
Am J Respir Crit Care Med. 2017 Feb 1;195(3):302-313
pubmed: 27556234
Clin Pediatr (Phila). 2010 Dec;49(12):1111-6
pubmed: 20724325
Eur Respir Rev. 2015 Jun;24(136):361-9
pubmed: 26028647
AMIA Annu Symp Proc. 2008 Nov 06;:308-12
pubmed: 18999057
Ann Am Thorac Soc. 2018 Aug;15(8):955-961
pubmed: 29863899
Ann Allergy Asthma Immunol. 2015 Nov;115(5):408-14
pubmed: 26392047
Eur Respir J. 2018 May 3;51(5):
pubmed: 29650557
Eur Respir J. 2021 Aug 5;58(2):
pubmed: 33542055
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Am J Health Syst Pharm. 2007 May 15;64(10):1054-61
pubmed: 17494905
J Allergy Clin Immunol. 2007 Jun;119(6):1454-61
pubmed: 17481716
J Asthma. 2020 Jul;57(7):736-742
pubmed: 31062634
J Asthma. 2012 Feb;49(1):90-7
pubmed: 22149141
Nat Rev Immunol. 2015 Jan;15(1):57-65
pubmed: 25534623
J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):144-153.e8
pubmed: 27665383
Prim Care Respir J. 2007 Feb;16(1):22-7
pubmed: 17297523
Am J Respir Crit Care Med. 2019 Nov 1;200(9):1102-1112
pubmed: 31166782
J Asthma. 2019 Jul;56(7):704-710
pubmed: 29969928
Ann Emerg Med. 2001 Aug;38(2):123-8
pubmed: 11468605